anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A drug delivery system is disclosed. The drug delivery system includes a recognitive polymeric hydrogel through which a drug is delivered by contacting biological tissue. The recognitive polymeric hydrogel is formed using a bio-template, which is a drug or is structurally similar to the drug, functionalized monomers, preferably having complexing sites, and cross-linking monomers, which are copolymerized using a suitable initiator. The complexing sites of the recognitive polymeric hydrogel that is formed mimic receptor sites of a target biological tissue, biological recognition, or biological mechanism of action. A system in accordance with some embodiments is a contact lens for delivering a drug through contact with an eye. In some embodiments, the drug is an anti-microbial, such as an anti-fungal agent for treatment of large animals. In some embodiments, a comfort molecule hyaluronic acid (HA) is delivered. In some embodiments, ketotifen fumarate (anti-histamine) and/or diclofenac sodium (anti-inflammatory) are delivered.
Cefazolin 2g (or 3g if greater than 120kg body weight) will be given within an hour of surgery. The intraoperative dose at 4 hours after the first dose or upon wound closure (whatever comes first) and the five post-operative doses in the long-term arms will be 2g every 8 hours. Vancomycin will be dosed at roughly 15mg/kg body weight intravenously, i.e. 1g or 1.5g if greater than 85kg body weight and is to be administered within 60-90 minutes of the surgical procedure. The same dose will be used for the 3 post-operative doses in the long-term arm.
The invention belongs to the fields of natural medicines and cosmetics, and discloses applications of Chinese torreya essential oil in preparing medicines for treating inflammation-related diseases, and applications of Chinese torreya essential oil as the functional component in the cosmetics, so that the anaphylactic reaction of the cosmetics is reduced, and the anti-inflammatory repairing capacity of the skin is improved. The animal inflammation experiment proves that no matter after Chinese torreya essential oil is taken orally or externally applied, the mouse acute inflammation caused by egg white can be obviously inhibited, and in addition, the mouse acute inflammation caused by carrageenin also can be obviously inhibited. Chinese torreya essential oil is prepared from Chinese torreya aril through a distillation method, a cold pressing method, a solvent extraction method or a CO2 supercritical extraction method. The requirements for the quality of the Chinese torreya essential oil are as follows: the colourless or chartreuse liquid adopted has the characteristic aroma of Chinese torreya fruits, and has the relative density (at 20 DEG C/20 DEG C) being 0.850-0.860, and the sum of the contents of the characteristic components alpha-pinene and limonene is greater than or equal to 30%. The invention discloses the novel applications of Chinese torreya essential oil in preparing the anti-inflammatory medicines or cosmetics. In addition, by comparing the advantages and disadvantages of different extraction methods of Chinese torreya essential oil, the invention provides a preferable preparation method of Chinese torreya essential oil.
The present invention relates to novel ABC1 polypeptides and nucleic acid molecules encoding the same. The invention also relates to recombinant vectors, host cells, and compositions comprising ABC1 polynucleotides, as we ll as to methods for producing ABC1 polypeptides. The invention also relates to  antibodies that bind specifically to ABC1 polypeptides. In addition, the invention relates to methods for increasing cholesterol efflux as well as to  methods for increasing ABC1 expression and activity. The present invention further relates to methods for identifying compounds that modulate the expression of ABC1 and methods for detecting the comparative level of ABC1 polypeptides and polynucleotides in a mammalian subject. The present inventi on also provides kits and compositions suitable for screening compounds to determine the ABC1 expression modulating activity of the compound, as well a s kits and compositions suitable to determine whether a compound modulates ABC 1- dependent cholesterol efflux.
A shampoo preparation comprises (a) salicyclic acid, (b) at least one anionic surface active agent and (c) one or more alkyl (C1 to C6) esters of phthalic acid and/or adipic acid. Methyl, ethyl, isopropyl and n-butyl esters are specified, anionic agents include, for example, dioctyl sodium sulphosuccinate, sodium laurylsulphoacetate, sodium laurylsulphate, sodium tetradecylsulphate, sodium dodecylsulphate, sodium dodecylbenzenesulphonate and triethanolamine laurylsulphate and the salicylic acid may be introduced in the form of a derivative hydrolysable thereto. Water may also be present and other additives may include cetanol, lanolin, glyceryl monostearate, lecithin, perfumes, colouring agents, thickening agents and antiseptic agents, e.g. benzoic acid and alkyl esters of p-hydroxybenzoic acid and hexachloro-phenol.ALSO:An antimicrobial shampoo composition comprises a) salicylic acid, b) at least on anionic surface active agent and c) one or more alkyl (C1 to C6) esters of phthalic acid and/or adipic acid. The antiseptic effect caused by the salicyclic acid may be accentuated by including agents such as benzoic acid and alkyl esters of p-hydroxybenzoic acid and hexachlorophenol.  Water may also be present and other additives include cetanol, lanolin, glyceryl monostearate, lecithin, perfumes, and colouring and thickening agents.
The invention belongs to the technical field of traditional Chinese medicines and in particular relates to a traditional Chinese medicine preparation for adjusting hypertension, hyperlipemia and hyperglycemia. The traditional Chinese medicine preparation is prepared from the following components in parts by weight: 8-20 parts of apium graveolens, 8-20 parts of roots of red-rooted salvia, 5-15 parts of sanchi flowers, 10-30 parts of red rhodobryum, 10-30 parts of roots of kudzu vines, 5-15 parts of anoectochilus formosanus, 5-15 parts of radix cynanchi bungei, 5-15 parts of dendrobe and 20-30 parts of sweet potato leaves. The traditional Chinese medicine preparation is obtained by combining the multi-year clinical experience summary of the investor through repeated experiments on the basis of the secret prescription handed down from ancestors, so that the preparation has a special curative effect on the refractory hypertension, hyperlipemia and hyperglycemia. By scientifically combining the plurality of drugs and compressively applying the preparation, the active ingredients of the drug can quickly enter blood circulation, so that blood cholesterol is lowered, thrombogenesis is blocked, coronary artery is expanded, blood flow volume is increased, myocardial ischemia tolerance is improved, cerebral infarction is improved and damaged cranial nerves are recovered, and therefore, patients with hypertension, hyperlipemia and hyperglycemia are quickly recovered. The traditional Chinese medicine preparation disclosed by the invention has the special curative effect to hypertension, hyperlipemia, diabetes mellitus, brain atrophy, cerebral thrombosis, coronary heart disease, cerebral arteriosclerosis and sequela of apoplexy. Moreover, the traditional Chinese medicine preparation is quick to become effective, short in treatment course, high in cure rate and small in expense.
An implanted medical device (e.g. infusion pump) and an external device communicate with one another via telemetry messages that are receivable only during windows or listening periods. Each listening period is open for a prescribed period of time and is spaced from successive listening periods by an interval. The prescribed period of time is typically kept small to minimize power consumption. To increase likelihood of successful communication, the window may be forced to an open state, by use of an attention signal, in anticipation of an incoming message. To further minimize power consumption, it is desirable to minimize use of extended attention signals, which is accomplished by the transmitter maintaining an estimate of listening period start times and attempting to send messages only during listening periods. In the communication device, the estimate is updated as a result of information obtained with the reception of each message from the medical device.
Sunprotection applicator for applying sunprotection oil constituted by a small cloth saturated with sunprotection oil. The cloth is in its turn before the use enclosed in a disposable package. This is torn up and the cloth is used, whereafter package as well as cloth can be thrown away. In a common, several sunprotection applicators containing package several cloths with different sunprotection factors can be kept so that an adaption can be done to the needs. Since the sunprotection applicator i.e. the cloth and oil is contained hermetically and closed up to the use a particularily good hygiene is obtained and it is not necessary to add anti-oxidizing agents to the oil, which is the case with sun oils in bottles.
The significance of long non-coding RNA (ncRNAs) in the initiation and progression of diabetic nephropathy (DN) has attracted much interest. The purpose of this work was to ascertain the role of LINC01232 in cell models and animal models of DN. C57BL/6 J mice were administered with streptozotocin (STZ) to develop animal models of DN, and mouse glomerular mesangial cells (MCs) were exposed to high glucose (HG) to establish cell models of DN. Expression levels of LINC01232, miR-1250-3p and MSH2 were identified by quantitative real-time PCR (qPCR) or western blotting. Fibrosis-related proteins were quantified by western blotting. MC proliferative capacity was checked by EdU assay. DN progression and fibrosis level in animal models were assessed by hematoxylin and eosin (HE) and Masson staining. The potential binding sites between miR-1250-3p and LINC01232 or MSH2 were examined by dual-luciferase reporter assay. LINC01232 expression was heightened in kidney tissues of DN patients. Its overexpression in HG-treated MCs alleviated MC proliferation and fibrosis. Overexpression of LINC01232 alleviated the pathological state of glomerular hypertrophy, MC hyperplasia, basement membrane thickening, and fibrosis in the DN models. LINC01232 bound to miR-1250-3p and competed for miR-1250-3p binding sites with MSH2. LINC01232 overexpression decoyed miR-1250-3p to increase MSH2 expression, and MSH2 depletion restored LINC01232 overexpression-inhibited MC proliferation and fibrosis. LINC01232 alleviated the mesangial cell proliferation and fibrosis in the progression of DN by targeting miR-1250-3p/MSH2 pathway.
PURPOSE:To efficiently concentrate tea components without losing the bioactvitity in the extraction liquid or arom. component of tea by concentrating the tea components of the leaves of Eucommiales by using a vapor permeation method membrane sepn. or pervaporation method membrane separation membrane under low-temp. and reduced pressure conditions. CONSTITUTION:The dried leaves of the Eucommiales as raw materials are first extracted in a boiling state by using water. This extraction liquid is put into a feed tank 1 and while the liquid temp. is regulated by a heating coil 2, the primary side is deaerated by a vacuum pump 11 to evaporate the sample liquid components. The vacuum degrees P1, P2 and liquid temp. To on the primary side and secondary side and the temps. T1, T2 of an evaporation chamber on the primary side and secondary side are controlled at this time. Then the arom. components and active components derived from the Eucommiales are then concentrated without impairing the quality at about room temp.
AIM: To investigate visual (perceptual) function and functional vision in children with unilateral cerebral palsy (CP) and children with neurotypical development (NTD).
METHOD: Fifty children with unilateral CP (mean age 11 years 11 months, SD 2 years 10 months, range 7-15 years; 27 males; 26 left-sided unilateral CP; Manual Ability Classification System [MACS] levels: I, 27; II, 16; III, 7) and 50 age- and sex-matched children with NTD participated in a cross-sectional study. Visual acuity, stereoacuity, and visual-perceptual functions were measured with standardized clinical tests. Functional vision was assessed in children with unilateral CP with the Flemish cerebral visual impairment questionnaire (FCVIQ). Group differences were investigated with Mann-Whitney U tests, Kruskal-Wallis tests, and the relative effect sizes r, η2 respectively. Correlations between visual assessments and the FCVIQ were investigated with Spearman's rank correlations.
RESULTS: The total group of children with unilateral CP showed reduced visual acuity compared with children with NTD (p = 0.02, r = 0.23). Only children with left-sided unilateral CP scored lower than those with NTD on stereoacuity (p < 0.01, r = 0.36). Children with right/left-sided unilateral CP scored significantly lower than those with NTD on visual-perceptual functions (p = 0.001-0.02), with large effect sizes on visuomotor integration and visual closure (both r = 0.57). Children with unilateral CP classified in MACS level III showed significantly lower scores on visual-perceptual assessments than children classified in MACS level I. Stereoacuity and visual-perceptual functions negatively correlated with the FCVIQ, with the highest association with visual (dis)interest and anxiety-related behaviours.
INTERPRETATION: Multi-level visual profiling is warranted in the clinical intake of children with unilateral CP to detect visual impairments that further compromise their level of functioning.
* A treatment course consists of up to 2 cycles of VANFLYTA in combination with induction cytarabine and anthracycline, up to 4 cycles of VANFLYTA in combination with high-dose cytarabine consolidation, and up to 36 cycles of VANFLYTA as maintenance therapy [see Clinical Studies (14)] or until disease progression or unacceptable toxicity. VANFLYTA maintenance therapy should be initiated following consolidation chemotherapy upon blood count recovery of absolute neutrophil count >500/mm3 and platelet count >50,000/mm3.
  * See Table 1 for the recommended dosage of VANFLYTA by phase of therapy.



For patients who proceed to hematopoietic stem cell transplantation (HSCT), VANFLYTA should be stopped 7 days before the start of a conditioning regimen.

Administer VANFLYTA orally with or without food at approximately the same time each day. Swallow tablets whole. Do not cut, crush, or chew the tablets. If a dose of VANFLYTA is vomited, do not administer a replacement dose; wait until the next scheduled dose is due. If a dose of VANFLYTA is missed or not taken at the usual time, administer the dose as soon as possible on the same day and return to the usual schedule the following day. The patient should not take two doses on the same day.
POI is a loss of normal function before age 40, leading to infertility and hypergonadotropic hypoestrogenism. Currently, no optimal regimen exists to ameliorate ovarian function. The options to conceive genetically related offspring, are limited. Typically, affected patients end up with egg donation or adoption as an alternative .

A-PRP is plasma with a concentration of platelets above the blood baseline. A-PRP is developed from autologous blood. Within A-PRP, the concentration of platelets delivers an increased number of growth factors. PRP is becoming widely used in a variety of medical procedures seeking tissue remodeling and/or healing as an intervention. To date, applications in orthopedics, wound healing, dermatology and plastic surgery have gained general acceptance, primarily as the role of platelets and their activation in tissue repair and recovery has become better understood at a cellular and molecular level. This knowledge base provides a foundation for the present study because of the ready availability of FDA-approved kits for autologous PRP preparations and the recognition that the aging ovary acquires tissue pathologies in the form of wound healing and fibrosis as a result of repeat ovulations over the reproductive lifespan of women. Since PRP is an autologous blood product and is widely used via injection into various organs and tissues, safety concerns are minimal.

This study will involve adult women with a diagnosis of Premature ovarian insufficiency (POI) willing to perform an IVF/ICSI treatment. A-PRP will be prepared using Eclipse PRP Kit which is approved by US FDA for preparation of PRP. Consenting participants will receive injections of autologous Platelet Rich Plasma (A-PRP) in one randomly selected ovary under ultrasound guidance performed under IV sedation. As it is suggested that only mechanical stimulation by biopsy/scratch could be a potentially effective method for follicle activation, the other ovary will be injected with the same amount of Saline Solution (SS) as control, to replicate the same mechanical effect. Randomization will determine whether the right or left ovary will be treated. Follow up of the participants will be performed with transvaginal ultrasound and hormonal tests including AMH, FSH, LH, estradiol and progesterone, every 10 days for the next 3 months after the injection. If ovarian activity is detected, the participant will undergo an IVF treatment.
BACKGROUND: Nonspecific acute tropical febrile illnesses (NEATFI) are common in the Latin American tropics. Dengue, Chikungunya, Zika, Mayaro, and Usutu, among others, can coexist in the American tropics. This study aimed to surveil the arboviruses that cause| acute febrile syndrome in patients in the Meta department, Colombia.
METHODS: Between June 2021 and February 2023, an epidemiological surveillance study was conducted in the Llanos of the Meta department in Eastern Colombia.
RESULTS: One hundred patients in the acute phase with typical prodromal symptoms of NEATFI infection who attended the emergency department of the Villavicencio Departmental Hospital were included. ELISA tests were performed for Dengue, Usutu, Chikungunya, and Mayaro. RT-qPCR was performed to detect the arboviruses Usutu, Dengue, Zika, Mayaro, and Oropouche. The seroprevalence for the Chikungunya, Mayaro, and Usutu viruses was 41 % (28/68), 40 % (27/67), and 62 % (47/75), respectively. Seroconversion for Chikungunya was observed in one patient; two seroconverted to Mayaro and one to Usutu. The NS5 gene fragment of the Usutu virus was detected in nine febrile patients. RT-qPCR of the remaining arboviruses was negative. The clinical symptoms of the nine Usutu-positive patients were very similar to those of Dengue, Chikungunya, Zika, and Mayaro infections.
CONCLUSIONS: The pervasive detection of unexpected viruses such as Usutu and Mayaro demonstrated the importance of searching for other viruses different from Dengue. Because Usutu infection and Mayaro fever have clinical features like Dengue, a new algorithm should be proposed to improve the accuracy of acute tropical fevers.
The utilization of photothermal agents (PTAs) in photothermal therapy (PTT) is faced with challenges such as immune clearance and inadequate concentration, which consequently result in residual tumors and an increased risk of recurrence and metastasis. Conversely, excessive treatment can lead to heightened inflammation and inevitable harm to adjacent healthy tissues. To address these issues, we developed a nanosystem (M@PB) consisting of Prussian blue coated with tumor cell membrane for precise photothermal therapy (PTT) and subsequent reduction of inflammation. This system not only evades immune attack due to the homologous biological characteristics of the encapsulating cell membrane but also exhibits active targeting capabilities towards homologous tumors. Furthermore, it effectively reduces excessive phototoxicity by leveraging the distinctive photothermal and anti-inflammatory characteristics of PB nanoparticles. The resulting M@PB nanosystem demonstrates effective photothermal ablation under 808 nm laser irradiation while mitigating the inflammatory response through inhibiting of local production of inflammatory mediators. Our study provides valuable insights into achieving targeted PTT with high efficiency while minimizing post-treatment inflammatory responses.
Couples seeking infertility treatment are becoming more frequent. Paternal factor shows one of the infertility causes which may have a negative impact on reproductive outcomes. Intracytoplasmic sperm injection (ICSI) is thought to be the most effective way to treat infertility. Sperm morphology evaluation is a reliable predictor of male fertility while teratozoospermia index (TZI) is a unique expression of sperm morphological assessment. A higher rate of abnormal sperm morphology tends to have higher sperm chromosomal abnormality rates. The choice of high-quality sperm through sperm selection techniques is expected to improve ICSI outcomes. In this study, a total number of 264 couples were included and divided into 3 groups: (1) Males have normal TZI (Control group: 111 males have TZI \<1.6), (2) Males with high TZI and no sperm selection techniques are performed (NO-SS group: 63 males have TZI \>1.8), and (3) Males with high TZI and sperm selection techniques are performed (SS-group: 90 males have TZI \>1.8). The TZI was significantly (P\<0.000) higher in the NO-SS and SS-group as compared to the control group. The percentage of sperm DNA fragmentation SDF in the males of the SS group was significantly higher than the controls and NO-SS group (P=0.000). The fertilization (P=0. 039) and blastocyst development rates (P= 0. 041) are significantly higher in the SS group as compared to the NO-SS group in females aged \<35. A total of 1072 embryos were tested for preimplantation genetic testing for aneuploidy using NGS, although higher SDF in the males of the SS group, the embryo euploidy rates show that there is no significant difference between the SS group (56.35±3.46%) as compared to the control group (54.54±3.24%) and the NO-SS group (57.45±4.57%). In general, we found that sperm selection techniques are efficient techniques in increasing fertilization, blastocyst development rates, and euploidy rate in males with high teratozoospermia index and sperm DNA fragmentation combined.
Sodium Phenylacetate and Sodium Benzoate Injection 10% per 10% (a nitrogen binding agent) is a sterile, concentrated, aqueous solution of sodium phenylacetate and sodium benzoate. The pH of the solution is between 6 and 8. Sodium phenylacetate is a white to off-white powder. It is soluble in water. Sodium benzoate is a white to off-white powder that is readily soluble in water.

Figure 1

Sodium phenylacetate has a molecular weight of 158.14 and the molecular formula C8H7NaO2. Sodium benzoate has a molecular weight of 144.10 and the molecular formula C7H5NaO2.

Each mL of Sodium Phenylacetate and Sodium Benzoate Injection contains 100 mg of sodium phenylacetate and 100 mg of sodium benzoate, and Water for Injection. Sodium hydroxide and/or hydrochloric acid may have been used for pH adjustment.

Sodium Phenylacetate and Sodium Benzoate Injection is a sterile, concentrated solution intended for intravenous administration via a central venous catheter only after dilution [see Dosage and Administration (2)].
Exercise, Walking Program, and Health Self-Management Support. Participants will be visited at home once monthly and contacted by phone once weekly over 12 weeks to deliver the interventions.
Participants that are randomized γT treatment will take a short treatment course of gamma Tocopherol followed by chamber exposure with WSP. After a 4-week washout period, participants will cross over to the placebo treatment group.